Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life

References

• Scott DL, Steer S. The course of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21(5):943–967. doi:10.1016/j.berh.2007.05.00617870037
   PubMed Web of Science ®Google Scholar
• Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–1108. doi:10.1016/S0140-6736(10)60826-420870100
   PubMed Web of Science ®Google Scholar
• Lapadula G, Ferraccioli GF. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S102–S106.23078880
   PubMed Web of Science ®Google Scholar
• Leardini G, Salaffi F, Montanelli R, et al. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol. 2002;20(4):505–515.12175106
   PubMed Web of Science ®Google Scholar
• Benucci M, Rogai V, Atzeni F, Hammen V, Sarzi-Puttini PC, Migliore A. Costs associated with rheumatoid arthritis in Italy: past,presentand future. Clinicoecon Outcomes Res. 2016;8:33–41. doi:10.2147/CEOR.S9100626929654
   PubMed Web of Science ®Google Scholar
• Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625–639. doi:10.1002/acr.21641
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509. doi:10.1136/annrheumdis-2014-20531024161836
   PubMed Web of Science ®Google Scholar
• Sangiorgi D, Benucci M, Nappi C, Perrone V, Buda S, Degli Esposti L. Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis. Biologics. 2015;9:119–127. doi:10.2147/BTT.S8928626604680
   PubMedGoogle Scholar
• Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford). 2008;47(4):535–541. doi:10.1093/rheumatology/ken00718356179
   PubMedGoogle Scholar
• Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. J Rheumatol. 2008;35(9):1745–1753.18634164
   PubMed Web of Science ®Google Scholar
• Saraux A, Gossec L, Goupille P, et al. Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. Rheumatology (Oxford). 2010;49(4):733–740. doi:10.1093/rheumatology/kep43420081224
   PubMedGoogle Scholar
• Beresniak A, Ariza-Ariza R, Garcia-Llorente JF, Ramirez-Arellano A, Dupont D. Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain. Int J Inflam. 2011;2011:727634. doi:10.4061/2011/72763421785694
   PubMedGoogle Scholar
• Puolakka K, Blåfield H, Kauppi M, et al. Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland. Open Rheumatol J. 2012;6:38–43. doi:10.2174/187431290120601003822582103
   PubMedGoogle Scholar
• Russell A, Beresniak A, Bessette L, et al. Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin Rheumatol. 2009;28(4):403–412. doi:10.1007/s10067-008-1060-419089488
   PubMedGoogle Scholar
• Beresniak A, Baerwald C, Zeidler H, et al. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany. Clin Exp Rheumatol. 2013;31(3):400–408.23464803
   PubMed Web of Science ®Google Scholar
• Cimmino MA, Leardini G, Salaffi F, et al. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach. Clin Exp Rheumatol. 2011;29(4):633–641.21813056
   PubMed Web of Science ®Google Scholar
• Benucci M, Stam WB, Gilloteau I, et al. Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis. Clin Exp Rheumatol. 2013;31(4):575–583.23711100
   PubMed Web of Science ®Google Scholar
• Yuan Y, Trivedi D, Maclean R, Rosenblatt L. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. J Med Econ. 2010;13(1):33–41. doi:10.3111/1369699090350802120001596
   PubMedGoogle Scholar
• Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86–94. doi:10.1136/annrheumdis-2013-20384323962455
   PubMed Web of Science ®Google Scholar
• Gaultney J, Benucci M, Iannazzo S, Nappi C, Sion K, Sabater FJ. Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy. Expert Rev Pharmacoecon Outcomes Res. 2016;16(3):409–417. doi:10.1586/14737167.2016.110263626495961
   PubMed Web of Science ®Google Scholar
• Weijers L, Baerwald C, Mennini FS, et al. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada. Rheumatol Int. 2017;37(7):1111–1123. doi:10.1007/s00296-017-3739-928560470
   PubMed Web of Science ®Google Scholar
• Alemao E, Johal S, Al MJ, Rutten-van Mölken M. Cost-effectiveness analysis of abatacept compared with adalimumab on background methotrexate in biologic-naive adult patients with rheumatoid arthritis and poor prognosis. Value Health. 2018;21(2):193–202. doi:10.1016/j.jval.2017.05.02029477401
   PubMed Web of Science ®Google Scholar
• Neubauer AS, Minartz C, Herrmann KH, Baerwald CGO. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept. Clin Exp Rheumatol. 2018;36(3):448–454.29303709
   PubMed Web of Science ®Google Scholar
• Degli Esposti L, Favalli EG, Sangiorgi D, et al. Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy. Clinicoecon Outcomes Res. 2016;9:9–17. doi:10.2147/CEOR.S10873028053549
   PubMed Web of Science ®Google Scholar
• Meissner B, Trivedi D, You M, Rosenblatt L. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ. 2014;17(4):259–265. doi:10.3111/13696998.2014.89324124575891
   PubMedGoogle Scholar
• Brown S, Everett CC, Naraghi K, et al. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technol Assess. 2018;22(34):1–280. doi:10.3310/hta22340
   Web of Science ®Google Scholar
• Araújo FC, Gonçalves J, Fonseca JE. Pharmacoeconomics of biosimilars: what is there to gain from them? Curr Rheumatol Rep. 2016;18(8):50. doi:10.1007/s11926-016-0601-027402107
   PubMed Web of Science ®Google Scholar
• Cantini F, Benucci M. Switching from the bio-originators to biosimilar: is it premature to recommend this procedure? Ann Rheum Dis. 2019;78(4):e23. doi:10.1136/annrheumdis-2017-21282029288210
   PubMed Web of Science ®Google Scholar
• Gibofsky A, Skup M, Yang M, Mittal M, Macaulay D, Ganguli A. Short-term costs associated with non-medical switching in autoimmune conditions. Clin Exp Rheumatol. 2019;37(1):97–105.29998841
   PubMed Web of Science ®Google Scholar